安科生物:隆培促生长素审评已正常,此前沟通致暂停

新浪财经
Nov 20, 2025

投资者提问:隆培促生长素的进展贵司有没有跟进?据我了解,隆培促生长素处于审批暂停状态,需要提交资料,合规方面无法通过,2025年已经拿不到批号了。贵司对维升药业的投资是否包含相关上市承诺?董秘回答(安科生物SZ300009):您好,之前维升药业与药审中心就生产细节进行沟通,所以审评处于暂停状态,目前相关沟通已经结束,审评开关已经打开,隆培促生长素处于正常审评中。谢谢您的关注。查看更多董秘问答>>...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10